PRemature Acute Myocardial Infarction Register of Serbia
ConditionAcute Coronary Syndromes
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-45
SponsorCardiology Society of Serbia
About this trial
This observational multicentric national study aims to understand better acute myocardial infarction (heart attack) in young adults aged 45 years or younger in Serbia. By analyzing patient characteristics, medical history, test results, and treatment outcomes, the research seeks to identify factors contributing to heart attacks in this population and improve prevention and treatment strategies.
Participants will undergo routine tests during hospitalization, and specific blood samples will be collected for advanced analyses, including genetic testing. Follow-up will include periodic check-ins to monitor health outcomes.
The study will also explore differences in heart attack causes and outcomes in younger individuals compared to older populations, focusing on risk factors like smoking, cholesterol levels, and genetic predisposition.
Participation is voluntary, and all collected data will remain confidential.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
This national, multicentric, retrospective and prospective analysis would include patients with acute myocardial infarction (AMI) aged ≤ 45 years in Serbia
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Incidence and Prevalence of AMI in Patients Aged ≤ 45 Years in Serbia
The incidence and prevalence of AMI among patients aged ≤ 45 years in Serbia will be reported over the study period, expressed as the number of new and existing cases per 100,000 individuals annually Unit of Measure: "Cases per 100,000 individuals per year."
Time frame
From 01.January 2021.year to 31.December 2026.2
Demographic Characteristics and Prevalence of Atherosclerotic Risk Factors in Young AMI Patients
The demographic distribution (e.g., age, gender, socioeconomic status) and prevalence of standard atherosclerotic risk factors (e.g., smoking, diabetes, hypertension, hyperlipidemia) among AMI patients aged ≤ 45 years will be analyzed. Unit of Measure: "Percent of participants with each risk factor."
Time frame
From 01.January 2021.year to 31.December 2026.3
Angiographic Characteristics in Young AMI Patients
The presence and extent of obstructive and non-obstructive coronary artery disease, coronary lesions, dissection, and vasospasm will be assessed using angiographic findings. Unit of Measure: "Percent of participants with each angiographic characteristic."
Time frame
From 01.January 2021.year to 31.December 2026.Secondary outcomes
1
Characteristics of Atherosclerotic Plaque Using OCT or IVUS
Plaque characteristics, including degree of fibrosis, necrosis, calcification, and vulnerability, will be evaluated in a subset of patients using OCT or IVUS imaging. Unit of Measure: "Percent of plaques with specific characteristics (e.g., fibrosis, calcification)."
Time frame
From 01.January 2021.year to 31.December 2026.2
Prevalence of SCAD in Young AMI Patients
The prevalence of SCAD, including angiographic subtypes defined by current guidelines, will be assessed among participants. Unit of Measure: "Percent of participants diagnosed with SCAD."
Time frame
From 01.January 2021.year to 31.December 2026.3
Prevalence of Comorbidities in Young AMI Patients
The prevalence of comorbid conditions such as kidney disease, chronic lung diseases, systemic autoimmune diseases, and specific chronic therapies will be assessed. Unit of Measure: "Percent of participants with each comorbidity."
Time frame
From 01.January 2021.year to 31.December 2026.4
Prevalence of Inherited or Acquired Thrombophilia in MINOCA Patients
The presence of inherited or acquired thrombophilia in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) will be analyzed using genetic and laboratory tests. Unit of Measure: "Percent of MINOCA participants with thrombophilia."
Time frame
From 01.January 2021.year to 31.December 2026.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov